Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) posted its quarterly earnings data on Wednesday. Protagonist Therapeutics has a 52 week low of $50.49 and a 52 week high of $148.00. iSAM Funds UK Ltd purchased a new position in Protagonist Therapeutics during the 3rd quarter valued at about $207,000. FORA Capital LLC purchased a new position in Protagonist Therapeutics during the 3rd quarter valued at about $245,000. Featured ArticlesReceive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.